Why the study?
CRP has long been identified as a potential therapeutic target in AMI, with promising early results from registries and pilot trials supporting the need for a pivotal trial.
Does selective C-reactive protein apheresis reduce cardiovascular mortality or rehospitalization for heart failure in patients with acute myocardial infarction?
Does selective C-reactive protein apheresis reduce cardiovascular mortality or rehospitalization for heart failure in patients with acute myocardial infarction?
No takes yet. Share an insight, caveat, or question.
This paper outlines the rationale and design for a pivotal international randomized controlled trial evaluating the safety and efficacy of CRP apheresis in acute myocardial infarction.
Torzewski et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: